Table 1

Baseline characteristics among four different groups of patients with chronic hepatitis B

Overall (n=3801)Non-LC/non-HCC* (Group I) (n=2789)LC case† (Group II) (n=232)Non-LC HCC case‡ (Group III) (n=370)LC-HCC case§ (Group IV) (n=410)
Age, mean years (SD)46.4 (10.0)45.1 (9.64)46.4 (9.89)49.8 (11.0)51.5 (9.44)
Gender
 Female1418 (37.3)1125 (40.3)56 (24.1)131 (35.4)106 (25.9)
 Male2383 (62.7)1664 (59.7)176 (75.9)239 (64.6)304 (74.2)
Serum alanine aminotransferase level, U/L
 <453372 (88.7)2656 (95.2)200 (86.2)261 (70.5)255 (62.2)
 ≥45429 (11.3)133 (4.77)32 (13.8)109 (29.5)155 (37.8)
HBV DNA level, copies/mL
 <300853 (22.4)769 (27.6)31 (13.4)31 (8.38)22 (5.37)
 300–99991127 (29.7)943 (33.8)49 (21.1)83 (22.4)52 (12.7)
 10 000–99 999685 (18.0)498 (17.9)36 (15.5)79 (21.4)72 (17.6)
 ≥100 0001136 (29.9)579 (20.8)116 (50.0)177 (47.8)264 (64.4)
Serum HBsAg level, IU/mL¶
 <100939 (28.5)855 (30.7)31 (13.4)24 (22.9)29 (17.5)
 100–999911 (27.7)800 (28.7)60 (25.9)19 (18.1)32 (19.3)
 ≥10001442 (43.8)1134 (40.7)141 (60.8)62 (59.1)105 (63.3)
HBeAg serostatus¶
 Positive491 (14.9)320 (11.5)55 (23.7)41 (39.1)75 (45.2)
 Negative2801 (85.1)2469 (88.5)177 (76.3)64 (61.0)91 (54.8)
Viral genotype**
 C1034 (35.5)632 (31.2)80 (41.7)130 (41.1)192 (50.7)
 B+BC1877 (64.5)1392 (68.8)112 (58.3)186 (58.9)187 (49.3)
Precore G1896A mutant††
 Wild type478 (41.6)313 (37.1)64 (49.2)31 (50.8)70 (60.3)
 Mutant672 (58.4)530 (62.9)66 (50.8)30 (49.2)46 (39.7)
rs2296651 (S267F)
 GG3145 (82.7)2274 (81.5)192 (82.8)321 (86.8)358 (87.3)
 GA651 (17.1)510 (18.3)40 (17.2)49 (13.2)52 (12.7)
 AA5 (0.13)5 (0.18)0 (0)0 (0)0 (0)
  • *Patients with chronic hepatitis B without liver cirrhosis and HCC.

  • †Patients with chronic hepatitis B with liver cirrhosis but not yet developed HCC.

  • ‡Patients with chronic hepatitis B who developed non-cirrhotic HCC.

  • §Patients with chronic hepatitis B who developed cirrhotic HCC.

  • ¶Data were only available among the REVEAL-HBV cohort (n=3292).

  • **Data were available for individuals with detectable HBV DNA levels (≥300 copies/mL) in the REVEAL-HBV cohort.

  • ††Data were only available among the REVEAL-HBV cohort with HBV DNA levels ≥10 000 copies/mL.

  • HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; LC, liver cirrhosis.